Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Yujin Kwon 1, * , Minhee Park 1, * , Mi Jang 1, * , Seongju Yun 1 , Won Kyu Kim 1 , Sora Kim 2 , Soonmyung Paik 2 , Hyun Jung Lee 3 , Sungpil Hong 3 , Tae Il Kim 3 , Byungsoh Min 4 and Hoguen Kim 1 1 Department of Pathology and BK21 for Medical Science, Yonsei University College of Medicine, Seoul, Korea 2 Severance Biomedical Science Institute and BK21 for Medical Science, Yonsei University College of Medicine, Seoul, Korea 3 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea 4 Department of Surgery, Yonsei University College of Medicine, Seoul, Korea * These authors have contributed equally to this work Correspondence to: Hoguen Kim, email: hkyonsei@yuhs.ac Keywords: colon cancer, mRNA expression-based molecular classification, molecular subtype, consensus molecular subtype, DNA microarray Received: September 02, 2016 Accepted: March 22, 2017 Published: April 11, 2017 ABSTRACT Individualizing adjuvant chemotherapy is important in patients with advanced colorectal cancers (CRCs), and the ability to identify molecular subtypes predictive of good prognosis for stage III CRCs after adjuvant chemotherapy could be highly beneficial. We performed microarray-based gene expression analysis on 101 fresh-frozen primary samples from patients with stage III CRCs treated with FOLFOX adjuvant chemotherapy and 35 matched non-neoplastic mucosal tissues. CRC samples were classified into four molecular subtypes using nonnegative matrix factorization, and for comparison, we also grouped CRC samples using the proposed consensus molecular subtypes (CMSs). Of the 101 cases, 80 were classified into a CMS group, which shows a 79% correlation between the CMS classification and our four molecular subtypes. We found that two of our subtypes showed significantly higher disease-free survival and overall survival than the others. Group 2, in particular, which showed no disease recurrence or death, was characterized by high microsatellite instability (MSI-H, 6/21), abundant mucin production (12/21), and right-sided location (12/21); this group strongly correlated with CMS1 (microsatellite instability immune type). We further identified the molecular characteristics of each group and selected 10 potential biomarker genes from each. When these were compared to the previously reported molecular classifier genes, we found that 31 out of 40 selected genes were matched with those previously reported. Our findings indicate that molecular classification can reveal specific molecular subtypes correlating with clinicopathologic features of CRCs and can have predictive value for the prognosis for stage III CRCs with FOLFOX adjuvant chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metagenes and molecular pattern discovery using matrix factorization
Brunet, J.-P., Tamayo, P., Golub, T. R., & Mesirov, J. P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308531101 · Cited by 2,183
Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001453 · Cited by 1,507
Tetraspanin functions and associated microdomains
Hemler, M. E. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1736 · Cited by 1,355 · cited 1×
“TSPAN6 has been associated with tumor cell migration [27, 28], and over-expression is linked to worsened survival in CRC patients.”
BackgroundLee, H.-J., Suk, J.-E., Patrick, C., Bae, E.-J., Cho, J.-H., Rho, S., Hwang, D., Masliah, E., & Lee, S.-J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081125 · Cited by 877 · cited 1×
“Based on these normalized intensities, genes differentially expressed in non-neoplastic colon mucosal tissues and in colon tumors were determined using the integrated statistical method previously reported [31].”
MethodSelf-citationDe Sousa E Melo, F., Wang, X., Jansen, M., Fessler, E., Trinh, A., de Rooij, L. P. M. H., de Jong, J. H., de Boer, O. J., van Leersum, R., Bijlsma, M. F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3174 · Cited by 771 · cited 4×
“[6] also divided CRCs into three molecular subtypes and found one (designated as CCS3 subtype) was related to poor differentiation and associated with poor prognosis.”
BackgroundMethodInfluential
Cited by
Microsatellite instability: a review of what the oncologist should know
Li, K., Luo, H., Huang, L., Luo, H., & Zhu, X. (2020) · Cancer Cell International · doi:10.1186/s12935-019-1091-8 · Cited by 509
ten Hoorn, S., de Back, T. R., Sommeijer, D. W., & Vermeulen, L. (2022) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab106 · Cited by 203
“Dismal OS and RFS for stage II and III CMS4 tumors were confirmed in 4 other studies (60,63,71,82), with 1 study reporting the lowest 5-year lymph node metastasis-free and RFS for T1 CMS4 tumors (66.”
ResultMethylation-Based Therapies for Colorectal Cancer
Cervena, K., Siskova, A., Buchler, T., Vodicka, P., & Vymetalkova, V. (2020) · Cells · doi:10.3390/cells9061540 · Cited by 57
Morris, J. S., Luthra, R., Liu, Y., Duose, D. Y., Lee, W., Reddy, N. G., Windham, J., Chen, H., Tong, Z., Zhang, B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2403 · Cited by 36
Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant
Fichtner, M., Bozkurt, E., Salvucci, M., McCann, C., McAllister, K. A., Halang, L., Düssmann, H., Kinsella, S., Crawford, N., Sessler, T., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03232-z · Cited by 28
Metadata
- Authors
- Kwon, Y., Park, M., Jang, M., Yun, S., Kim, W. K., Kim, S., Paik, S., Lee, H. J., Hong, S., Kim, T. I., Min, B., & Kim, H.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-04-11
- Volume
- 8
- Issue
- 24
- Pages
- 39367-39381
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2605783169
- Cited by
- 43
- References
- 5
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype. https://app.cochat.ai/papers/10.18632/oncotarget.17023
- The paper
- Kwon, Y., Park, M., Jang, M., Yun, S., Kim, W. K., Kim, S., Paik, S., Lee, H. J., Hong, S., Kim, T. I., Min, B., & Kim, H. (2017). Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype. Oncotarget. https://doi.org/10.18632/oncotarget.17023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.